



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: October 16, 2009

To: Primary Clinical Research Associates

From: Alicia Elsing
Research Protocol Specialist III

Re: N0821, A Phase II First-Line Study of a Combination of Pemetrexed, Carboplatin and Bevacizumab in Advanced Nonsquamous NSCLC Evaluating Efficacy and Tolerability in Elderly Patients (Age \geq 70 yrs) with Good Performance Status (PS $<$ 2)

The Evaluation/Treatment Form has been updated as follows:

Form Title	Brief Description of Edit
Evaluation/Treatment Form	<ul style="list-style-type: none">• Added field for creatinine clearance

If you have any questions, please feel free to contact me at elsing.alicia@mayo.edu or 507-538-3893.

Enclosure